[1]Our Core Product REC603, a HPV 9-valent vaccine, obtained the umbrella IND approval from the NMPA in July 2018. The umbrella IND approval covers all three phases (phase I, II and III) of clinical trials of REC603. Based on communications with the CDE of the NMPA, the NMPA has no objection for us to proceed with phase III clinical trial in China directly. Accordingly, the Company did not conduct any phase II clinical trial for REC603.